SCHEMBL147833

SCHEMBL147833

NC(=O)c1c(-c2ccccc2F)ccc2c1[nH]c1ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM3 Q86V86 2/20 0.50
PIM1 P11309 1/20 0.50
PARP14 Q460N5 7/20 0.46
BTK Q06187 3/20 0.44
PARP1 P09874 1/20 0.43
JAK2 O60674 2/20 0.42
AURKA O14965 1/20 0.42
LCK P06239 1/20 0.42
LYN P07948 1/20 0.42
KIT P10721 1/20 0.42
CDK2 P24941 1/20 0.42
TYK2 P29597 1/20 0.42
TEC P42680 1/20 0.42
TXK P42681 1/20 0.42
BMX P51813 1/20 0.42
ITK Q08881 1/20 0.42
CDK4 P11802 1/20 0.42
CCND1 P24385 1/20 0.42
GRM2 Q14416 1/20 0.41
TUBB4A P04350 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL123665 0.78 BTK (0.64) PIM3PIM1BTKPARP1JAK2
SCHEMBL148354 0.78 PIM1 (0.45) PIM3PIM1PARP14BTKTP53
SCHEMBL7723752 0.77 PIM3 (0.47) PIM3PIM1PARP14BTKJAK2
SCHEMBL148605 0.77 PIM1 (0.44) PIM3PIM1PARP14BTKKDM4E
SCHEMBL28165763 0.77 PIM3 (0.55) PIM3PIM1PARP14JAK2TP53
SCHEMBL148467 0.76 TDO2 (0.54) PIM3PIM1PARP14BTKPARP1
SCHEMBL149085 0.76 BCHE (0.46) PIM3PIM1PARP14PARP1JAK2
SCHEMBL28481860 0.76 KIF11 (0.56) PIM3PIM1PARP14PARP1JAK2
SCHEMBL8910145 0.75 PIM3 (0.57) PIM3PIM1PARP14PARP1JAK2
SCHEMBL146256 0.74 BTK (0.57) PARP14BTKMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PIM3 102/4885PIM1 90/4885PARP14 649/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PIM3 102/4885PIM1 90/4885PARP14 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.